ArticleJournal of applied clinical medical physics2020
A simple, yet novel hybrid-dynamic conformal arc therapy planning via flattening filter-free beam for lung stereotactic body radiotherapy.
Article in Journal of applied clinical medical physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Novel DCAT plans in stereotactic body radiotherapy for stage I/II centrally located non-small-cell lung cancer.Scientific reports · 2026Article
- Optimizing lung SBRT delivery: A hybrid approach combining dynamic conformal arc (DCA) and volumetric modulated arc therapy (VMAT) techniques.Journal of applied clinical medical physics · 2025Article
- Dynamic conformal arc radiotherapy for locally advanced lung cancer: a comparison with static-beam conformal radiotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Article
- A novel CRT-IMRT-combined (Co-CRIM) planning technique for peripheral lung stereotactic body radiotherapy in pinnacle treatment planning system.Journal of applied clinical medical physics · 2021Article
- Novel Clinically Weight-Optimized Dynamic Conformal Arcs (WO-DCA) for Liver SBRT: A Comparison with Volumetric Modulated Arc Therapy (VMAT).Therapeutics and clinical risk management · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDue to multiple beamlets in the delivery of highly modulated volumetric arc therapy (VMAT) plans, dose delivery uncertainties associated with small-field dosimetry and interplay effects can be concerns in the treatment of mobile lung lesions using a single-dose of stereotactic body radiotherapy (SBRT). Herein, we describe and compare a simple, yet clinically useful, hybrid 3D-dynamic conformal arc (h-DCA) planning technique using flattening filter-free (FFF) beams to minimize these effects. MATERIALS AND
methodsFifteen consecutive solitary early-stage I-II non-small-cell lung cancer (NSCLC) patients who underwent a single-dose of 30 Gy using 3-6 non-coplanar VMAT arcs with 6X-FFF beams in our clinic. These patients' plans were re-planned using a non-coplanar hybrid technique with 2-3 differentially-weighted partial dynamic conformal arcs (DCA) plus 4-6 static beams. About 60-70% of the total beam weight was given to the DCA and the rest was distributed among the static beams to maximize the tumor coverage and spare the organs-at-risk (OAR). The clinical VMAT and h-DCA plans were compared via RTOG-0915 protocol for conformity and dose to OAR. Additionally, delivery efficiency, accuracy, and overall h-DCA planning time were recorded.
resultsAll plans met RTOG-0915 requirements. Comparison with clinical VMAT plans h-DAC gave better target coverage with a higher dose to the tumor and exhibited statistically insignificance differences in gradient index, D
conclusionDue to no beam modulation through the target, h-DCA plans avoid small-field dosimetry and MLC interplay effects and resulting in enhanced target coverage by improving tumor dose (characteristic of FFF-beam). The h-DCA simplifies treatment planning and beam on time significantly compared to clinical VMAT plans. Additionally, h-DCA allows for the real time target verification and eliminates patient-specific VMAT quality assurance; potentially offering cost-effective, same or next day SBRT treatments. Moreover, this technique can be easily adopted to other disease sites and small clinics with less extensive physics or machine support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.